Oncotarget

Research Papers:

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

Shota Fukuoka, Takashi Kojima _, Yoshikatsu Koga, Mayumi Yamauchi, Masayuki Komatsu, Rie Komatsuzaki, Hiroki Sasaki, Masahiro Yasunaga, Yasuhiro Matsumura, Toshihiko Doi and Atsushi Ohtsu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:11020-11029. https://doi.org/10.18632/oncotarget.14209

Metrics: PDF 1938 views  |   HTML 2084 views  |   ?  


Abstract

Shota Fukuoka1,5, Takashi Kojima1, Yoshikatsu Koga2, Mayumi Yamauchi1, Masayuki Komatsu3, Rie Komatsuzaki3, Hiroki Sasaki3, Masahiro Yasunaga2, Yasuhiro Matsumura2, Toshihiko Doi1, Atsushi Ohtsu4,5

1Division of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

2Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan

3Department of Translational Oncology, Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokyo, Japan

4Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

5Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan

Correspondence to:

Takashi Kojima, email: [email protected]

Keywords: esophageal squamous cell carcinoma, epidermal growth factor receptor, Sym004

Received: June 15, 2016     Accepted: December 16, 2016     Published: December 26, 2016

ABSTRACT

Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in the majority of esophageal squamous cell carcinomas (ESCCs), we investigated the efficacy of Sym004 in human ESCC cell lines. Forty eight ESCC cell lines were treated with three kinds of anti-EGFR antibodies (Sym004, cetuximab, and panitumumab). Genetic background was investigated by next generation sequencing. The internalization of anti-EGFR antibodies into ESCC cells and inhibition of the EGFR signaling cascade by anti-EGFR antibodies were investigated in vitro. Furthermore, growth inhibition by anti-EGFR antibody treatment was investigated in vitro and in vivo. Sym004 treatments were more effective at inducing EGFR internalization and degradation than the two other anti-EGFR antibodies. Sym004 was more sensitive significantly to cell lines with EGFR gene amplification than those without amplification (P = 0.002). Growth inhibition of Sym004 was greater than in that of cetuximab or panitumumab in vitro and in vivo. These studies showed that Sym004 exhibited antitumor activity in some ESCC cell lines in preclinical settings and warrant a clinical evaluation in patients with ESCC. EGFR amplification is a potential biomarker of response to Sym004.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14209